Human breast cancer resisting recombination immunotoxin M4G3/ScFv-PE40

Abstract

The present invention is one kind of prepared recombinant targeted toxin, M4G3 / ScFv-PE40, for the targeting treatment of breast cancer, and belongs to the field of biotechnology. The recombinant targeted toxin M4G3 / ScFv-PE40 is prepared through fusing and co-expressing mouse anti-human breast cancer single strand antibody M4G3-scFv and Bacillus pyocyaneus epitoxin PE40. The recombinant targeted toxin can recognize and combine with T47D human breast cancer cell specifically in dose dependence, and has obvious cytotoxicity on T47D human breast cancer cell in dose-effect relationship and highest inhibiting rate up to 42.63 %, so that it may be applied in biological treatment of breast cancer.

Description

[technical field] [0001] The invention belongs to the field of biotechnology, and specifically prepares a recombinant immunotoxin M4G3 / ScFv-PE40 for targeted therapy of breast cancer. [Background technique] [0002] Breast cancer is a malignant tumor that has plagued female patients for a long time, and its clinical incidence is quite high. Clinical treatment is mainly based on surgical treatment and radiotherapy and chemotherapy. In recent years, people have raised objections to the traditional radical mastectomy for breast cancer, because although the operation can control the primary cancer, at least half of the breast cancer patients have hematogenous metastasis after the operation, which leads to treatment failure. Serious side effects such as cytotoxicity such as myelosuppression and cardiotoxicity of systemic chemotherapy also make the treatment ineffective. Therefore, it is of great significance to seek a completely effective targeted therapy. [0003] Monoclonal ...

AI Technical Summary

Problems solved by technology

Then the transposition is completed by the DII region, enters the interior of the cell, is transported to the endoplasmic reticulum through the Golgi apparatus, and then translocates to the cytoplasm, where DomainIII of PE can make the ADP ribose group of peptide chain elongation factor-2 (EF-2) It cannot interact with ribosomes, and the peptide chain cannot be extended, thus hindering protein synthesis and leading to programmed death of eukaryotic cells

Images